174 related articles for article (PubMed ID: 30992690)
1. The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
Salehzadeh S; Guerrini F; Pizzano U; Grassi S; Ciabatti E; Iovino L; Buda G; Caracciolo F; Benedetti E; Orciuolo E; Pelosini M; Consani G; Carulli G; Metelli MR; Martini F; Mazziotta F; Mazzantini E; Rossi P; Tavarozzi R; Ricci F; Petrini M; Galimberti S
Cancer Cell Int; 2019; 19():83. PubMed ID: 30992690
[TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
4. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
5.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
6. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
7. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.
Patkar N; Kakirde C; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Deshpande N; Kadechkar S; Chatterjee G; Kannan S; Shetty D; Gokarn A; Punatkar S; Bonda A; Nayak L; Jain H; Bagal B; Menon H; Sengar M; Khizer SH; Khattry N; Tembhare P; Gujral S; Subramanian P
Front Oncol; 2019; 9():450. PubMed ID: 31263671
[No Abstract] [Full Text] [Related]
8. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
9. [Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia].
Qin W; Chao HY; Cai XH; Lu XZ; Liu J; Wu P; Chen MY
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3152-3157. PubMed ID: 31694106
[No Abstract] [Full Text] [Related]
10. The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively.
Heiblig M; Duployez N; Marceau A; Lebon D; Goursaud L; Plantier I; Stalnikiewich L; Cambier N; Balsat M; Fossard G; Labussière-Wallet H; Barraco F; Ducastelle-Lepretre S; Sujobert P; Huet S; Hayette S; Ghesquières H; Thomas X; Preudhomme C
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33947035
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
12. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
13. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
14. TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.
Tian X; Xu Y; Yin J; Tian H; Chen S; Wu D; Sun A
Int J Hematol; 2014 Jul; 100(1):96-104. PubMed ID: 24859829
[TBL] [Abstract][Full Text] [Related]
15. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
16. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Othman J; Potter N; Ivey A; Tazi Y; Papaemmanuil E; Jovanovic J; Freeman SD; Gilkes AF; Gale RE; Rapoz-D'Silva T; Runglall M; Kleeman M; Dhami P; Thomas I; Johnson S; Canham J; Cavenagh JD; Kottaridis P; Arnold C; Ommen HB; Overgaard UM; Dennis M; Burnett AK; Wilhelm-Benartzi CS; Huntly BJ; Russell NH; Dillon RJ
Blood; 2024 May; ():. PubMed ID: 38691678
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of
Minetto P; Candoni A; Guolo F; Clavio M; Zannier ME; Miglino M; Dubbini MV; Carminati E; Sicuranza A; Ciofini S; Colombo N; Pugliese G; Marcolin R; Santoni A; Ballerini F; Lanino L; Cea M; Gobbi M; Bocchia M; Fanin R; Lemoli RM
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374216
[TBL] [Abstract][Full Text] [Related]
18. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
19. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
El Hussein S; DiNardo CD; Takahashi K; Khoury JD; Fang H; Furudate K; Lyapichev KA; Garces S; Kanagal-Shamanna R; Ok CY; Patel KP; Routbort MJ; Ravandi F; Medeiros LJ; Wang SA; Loghavi S
Bone Marrow Transplant; 2022 Mar; 57(3):370-376. PubMed ID: 34992253
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database.
Xu J; Zhang Y; Hu J; Ren Y; Wang H
Hematology; 2020 Dec; 25(1):79-84. PubMed ID: 32019476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
